L-lactyl-L-proline | 126204-49-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-lactyl-L-proline
• 英文别名: 1-[(S)-2-Hydroxy-1-oxopropyl]-L-proline；1-[(S)-2-hydroxyl-1-oxopropyl]-L-proline；(2S)-1-[(2S)-2-hydroxypropanoyl]pyrrolidine-2-carboxylic acid
• CAS: 126204-49-7
• 化学式: C₈H₁₃NO₄
• 分子量: 187.196
• InChiKey: JFSJTTPJLNOARZ-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-lactyl-L-proline 、 在 N-甲基吗啉 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到
  参考文献：
  名称：

  基于 2,3-二氨基糖脚手架的 Didemnin B 类似物的合成研究

  摘要：

  还原胺化、使用 BOP [(1H-1,2,3-benzotriazol-1-yloxy)tris(dimethylamino)-phosphonium hexafluorophosphate] 形成酰胺和通过 DCC（二环己基碳二亚胺）酯化是生成高级中间体的关键合成步骤。基于糖脚手架的二甲胺 B 类似物的制备 (2)。这种类似物应该可以深入了解 didemnin B 的生物活性构象。

  DOI：

  10.1002/jccs.200100001

文献信息

• Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04849414A1

  公开（公告）日：1989-07-18

  Compounds of the formula ##STR1## wherein X is various amino or imino acids and esters are disclosed. These compounds are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.

  公式为##STR1##的化合物中，X是各种氨基或亚氨基酸和酯。这些化合物由于其抑制血管紧张素转化酶的活性而可用作降压药物，根据X的定义，它们也可能由于其脑啡肽酶抑制活性而用作镇痛药。
• Phosphonate angiotensin converting enzyme inhibitors
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0239109A2

  公开（公告）日：1987-09-30

  Compounds of the formula wherein Z is and X is various amino or imino acids and esters are disclosed. These compounds are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.

  这些化合物具有抑制血管紧张素转换酶的活性，因此可用作抗高血压药；根据 X 的定义，它们还具有抑制脑啡肽酶的活性，因此也可用作镇痛药。
• Orally active phosphonyl hydroxyacyl prolines and processes for preparing phosphonyl hydroxyacyl prolines
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0229520A1

  公开（公告）日：1987-07-22

  Processes are disclosed for preparing phosphonyl hydroxyacyl prolines from a phosphonous acid or phosphonochloridate intermediate. The compounds prepared possess angiotension converting enzyme inhibition activity and are useful as antihypertensive agents. This invention is also directed to orally active antihypertensive agents of the formula wherein R1 is certain alkyl or aralkyl groups.

  本发明公开了从膦酸或膦酰氯中间体制备膦酰羟基酰基脯氨酸的工艺。 所制备的化合物具有血管紧张素转换酶抑制活性，可用作降压药。 本发明还涉及式中 R1 为特定烷基或芳烷基的口服活性降压药。
• Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0249445A2

  公开（公告）日：1987-12-16

  Compounds of the formula wherein X is various amino or imino acids and esters are disclosed. These compounds are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.

  式中的化合物 其中 X 为各种氨基酸或亚胺酸及酯类。由于具有血管紧张素转换酶抑制活性，这些化合物可用作抗高血压药，而且根据 X 的定义，由于具有脑啡肽酶抑制活性，这些化合物还可用作镇痛药。
• Processes for preparing phosphonyl hydroxyacyl prolines
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0350138A2

  公开（公告）日：1990-01-10

  Processes are disclosed for preparing phosphonyl hydroxyacyl prolines from a phosphonous acid or phosphonochloridate intermediate. The compounds prepared possess angiotension converting enzyme inhibition activty and are useful as anti­hypertensive agents. This invention is also directed to orally active antihypertensive agents of the formula wherein R₁ is certain alkyl or aralkyl groups.

  本发明公开了从膦酸或膦酰氯中间体制备膦酰羟基酰基脯氨酸的工艺。所制备的化合物具有血管紧张素转换酶抑制活性，可用作降压药。 本发明还涉及式如下的口服活性降压药 其中 R₁ 是某些烷基或芳烷基。